Abstract
Pretreatment with the dopamine D 2 receptor agonist quinpirole (0.025–2.5 mg/kg) produced a marked, dose-dependent, attenuation of the striatal Fos expression induced by the serotonin (5-Hydroxytryptamine, 5-HT) releasing agent fenfluramine (25 mg/kg). Quinpirole (2.5 mg/kg) was also able to drastically attenuate the striatal Fos response produced by injections of the direct 5-HT 1/2 receptor agonist N-(3-trifluoromethylphenyl)piperazine hydrochloride (TFMPP) (5 mg/kg), the selective 5-HT 2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI) (6.64 mg/kg), the 5-HT 1A/1B receptor agonist RU-24969 (5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)1 H-indole) (5 mg/kg), the μ-opioid receptor agonist morphine (5 mg/kg) and the muscarinic cholinergic receptor agonist pilocarpine (50 mg/kg). These results are in marked contrast to the previously reported ability of quinpirole to potentiate the response to D 1 dopamine receptor agonists and demonstrate that stimulation of D 2-like receptors can have differential effects on the Fos responses induced by various drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
